Markedshøring Oncotype Dx

  Address - Denmark

  Contact details - 565656565

  Tender notice no. - 76454545

  GT Ref Id - 100409359

  Document Type - Tender Notices

Description - Description: Region Zealand is assisting the Danish Health Technology Council in conducting a market consultation about the existence of any CE marked non-invasive prognostic test to guide adjuvant chemotherapy treatment decisions for individuals wit h hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage (I-IIIa) invasive breast cancer. The test provides two pieces of information: 1. the recurrence risk and 2. the benefit of adding chemotherapy in order to reduce the risk. The test analyses the expression of 21 genes in breast tumour tissue based on RT-PCR. It does not require additional tumour material beyond the surgically excised tissue.Th

Gt Ref Id - 100409359

Deadline - Jan 17, 2025